

Univ.-Prof. Dr. med. Stephan Grabbe

*07.07.1961

Director of the Department of Dermatology
Deputy Speaker of the FZI
Professor of Dermatology (W3)
Working Group Leader

Department of Dermatology
University Medical Center of the Johannes Gutenberg University Mainz
D-55131 Mainz, Langenbeckstr. 1, building 401
Tel: +49-6131-17 7112

stephan.grabbe@unimedizin-mainz.de

www.hautklinik-mainz.de/hautklinik/wissenschaftler/ag-prof-dr-grabbe.html



Career

- | | |
|------------|--|
| 1980-1987 | Studies in human medicine and philosophy at the Westf. Wilhelms University Münster and at the University of Wales, College of Medicine in Cardiff/GB |
| 1987 | Approbation as a physician, doctorate in medicine |
| 1987-1989 | Scientist at the University Dermatological Clinic Münster |
| 1988 | American State Examination for Medical Professionals (FMGEMS) |
| 1989-1992 | Postdoctoral Research Fellow, MGH-Harvard Cutaneous Biology Research Center, Harvard University, Boston |
| 1992-1998 | Scientist at the Center for Dermatology at the University of Münster |
| since 1994 | Head of a research laboratory for immune dermatology and tumor immunology at the Center for Dermatology of the University of Münster |
| 1995 | Specialist in dermatology, senior physician |
| 1996 | Habilitation |
| 1998-2000 | "Heisenberg" scholarship holder of the German Research Foundation, visiting scientist at the "Skin Disease Research Center", Harvard University, Boston |
| since 2000 | C3-Professor of Dermatology and Dermato-Oncology at the University of Münster |
| 2003 | Further training in hospital management, Academy of the University of Bochum |
| 2003-2007 | C4-Professor and Director of the Clinic for Dermatology, Venerology and Allergology at the University Hospital of Essen |
| since 2007 | W3-Professor and Director of the Department of Dermatology at the University Medical Center of the Johannes Gutenberg University Mainz |
| since 2009 | Speaker of the "Natural Science Medical Research Center", deputy speaker of the FZI as well as initiator of the translational biomedical training course "Transmed" of the University Medicine Mainz |

Selected Publications

Teschner D, Cholaszczyńska A, Ries F, Beckert H, Theobald M, **Grabbe S**, Radsak M, Bros M. CD11b regulates fungal outgrowth but not neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis. *Front Immunol.* 2019 Feb 4;10:123.

Balkow S, Heinz S, Schmidbauer P, Kolanus W, Holzmann B, **Grabbe S**, Laschinger M. LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming. *Blood.* 2010 Sep 16;116(11):1885-94

Krummen M, Balkow S, Shen L, Heinz S, Loquai C, Probst HC, **Grabbe S**. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. *J Leukoc Biol.* 2010 Jul;88(1):189-99

Varga G, Nippe N, Balkow S, Peters T, Wild MK, Seeliger S, Beissert S, Krummen M, Roth J, Sunderkötter C, **Grabbe S**. LFA-1 contributes to signal I of T-cell activation and to the production of T(h)1 cytokines. *J Invest Dermatol.* 2010 Apr;130(4):1005-12

Balkow S, Loser K, Krummen M, Higuchi T, Rothoef T, Apelt J, Tuettenberg A, Weishaupt C, Beissert S, **Grabbe S**. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. *Exp Dermatol.* 2009 Jan;18(1):78-87

Balkow S, Krux F, Loser K, Becker JU, **Grabbe S**, Dittmer U. Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. *Blood* 2007; 110 (12): 3949-58

Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoef T, Higuchi T, Beissert S, Wethmar K, Scharffetter-Kochanek K, Vestweber D, **Grabbe S**. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. *Blood.* 2007 Jan 15;109(2):661-9. Epub 2006 Sep 26

Rothoef T, Balkow S, Krummen M, Beissert S, Varga G, Loser K, Oberbanscheidt P, van den Boom F, **Grabbe S**. Structure and duration of contact between dendritic cells and T cells are controlled by T cell activation state. *Eur J Immunol.* 2006 Dec;36(12):3105-17

Riemann H, Loser K, Beissert S, Fujita M, Schwarz A, Schwarz T, **Grabbe S**. IL-12 breaks dinitrothiocyanobenzene (DNTB)-mediated tolerance and converts the tolerogen DNTB into an immunogen. *J Immunol.* 2005 Nov 1;175(9):5866-74

Gunzer M, Riemann H, Basoglu Y, Hillmer A, Weishaupt C, Balkow S, Benninghoff B, Ernst B, Steinert M, Scholzen T, Sunderkötter C, **Grabbe S**. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. *Blood.* 2005 Oct 1;106(7):2424-32. Epub 2005 Jun 23

Gunzer M, Weishaupt C, Hillmer A, Basoglu Y, Friedl P, Dittmar KE, Kolanus W, Varga G, **Grabbe S**. A spectrum of biophysical interaction modes between T cells and different antigen-presenting cells during priming in 3-D collagen and in vivo. *Blood.* 2004 Nov 1;104(9):2801-9. Epub 2004 Jul 15

Nashan D, Kocer B, Schiller M, Luger T, **Grabbe S**. Significant risk of a second melanoma in patients with a history of melanoma but no further predisposing factors. *Dermatology.* 2003;206(2):76-7

Pendl GG, Robert C, Steinert M, Thanos R, Eytner R, Borges E, Wild MK, Lowe JB, Fuhlbrigge RC, Kupper TS, Vestweber D, **Grabbe S**. Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. *Blood.* 2002 Feb 1;99(3):946-56